ViAqua Therapeutics

ViAqua TherapeuticsViAqua Therapeutics
ViAqua Therapeutics

ViAqua Therapeutics

Develops novel oral RNA delivery platforms for aquaculture health management, focusing on disease resistance.

Website
2014Active14
Rate
Advertise here

About

ViAqua Therapeutics addresses the critical need for effective and affordable health management solutions in the aquaculture industry. Their primary innovation is a novel oral delivery platform designed to deliver RNA, aiming to induce resistance to diseases like White Spot Shrimp Virus. This technology was co-developed with Skretting, a Nutreco company.

Technology stack

detected 2026-06-30
EmailMicrosoft 365
Stack
Wix
Observability
Sentry
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does ViAqua Therapeutics do?

ViAqua Therapeutics addresses the critical need for effective and affordable health management solutions in the aquaculture industry. Their primary innovation is a novel oral delivery platform designed to deliver RNA, aiming to induce resistance to diseases like White Spot Shrimp Virus. This technology was co-developed with Skretting, a Nutreco company.

How much funding has ViAqua Therapeutics raised?

ViAqua Therapeutics has raised a total of $13M in funding. The most recent round on record is Series A.

Where is ViAqua Therapeutics headquartered?

ViAqua Therapeutics is headquartered in Rehovot, Israel.

When was ViAqua Therapeutics founded?

ViAqua Therapeutics was founded in 2014.

What industry does ViAqua Therapeutics operate in?

ViAqua Therapeutics operates in Aquaculture, Seafood, Disease Management, Biotech, Life Sciences, RNA.

How many employees does ViAqua Therapeutics have?

ViAqua Therapeutics has approximately 14 people on record.

What is ViAqua Therapeutics's valuation?

StartupHub estimates ViAqua Therapeutics's effective valuation at $49.9M (range $31.4M to $75.3M, 11% confidence), based on comparable companies in the sector.